Autoimmune anti-N-methyl-D-aspartate (NMDA)-receptor encephalitis as a rare cause of complex psychiatric and neurologic manifestations. Case report and literature review
More details
Hide details
Student Research Group / Second Department of Anaesthesiology and Intensive Therapy, Medical University, Lublin, Poland
Second Department of Anaesthesiology and Intensive Therapy, Medical University, Lublin, Poland
Zuzanna Paluch   

Student Research Group of The Second Department of Anaesthesiology and Intensive Therapy, Medical University of Lublin, Lublin, Staszica 16, 20-081, Lublin, Poland
J Pre Clin Clin Res. 2022;16(3):75–78
Anti-N-methyl-D-aspartate (NMDA)-receptor encephalitis is an rare autoimmune disease associated with antibodies against of the NMDA receptors in the central nervous system. In more than half of patients, the disease coexists with ovarian teratoma. Most patients develop a multistage illness that progresses from psychosis, cognitive dysfunction, and seizures, into a state of unresponsiveness with catatonic features often associated with a movement disorder, autonomic instability, and central hypoventilation. The work presents a case of a 20-year-old female who was transferred to an intensive care unit from the Department of Psychiatry, due to a worsening state of consciousness with symptoms of respiratory failure and hemodynamic instability. In the previous clinic, the patient was treated for catatonic schizophrenia, with no results. The diagnosis of autoimmune encephalitis was made on the basis of the result of cerebrospinal fluid, in which antibodies to NMDA receptors were detected.
Paluch Z, Borys M, Krawczyk M, Duda P. Autoimmune anti-N-methyl-D-aspartate (NMDA)-receptor encephalitis as a rare cause of the complex psychiatric and neurologic manifestations. A case report and review of the literature. J Pre-Clin Clin Res. 2022; 16(3): 75–78. doi: 10.26444/jpccr/152424
Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-Daspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25–36. doi: 10.1002/ana.21050.
Braverman JA, Marcus C, Garg R. Anti-NMDA-receptor encephalitis: A neuropsychiatric syndrome associated with ovarian teratoma. Gynecol Oncol Rep. 2015;7;14:1–3. doi: 10.1016/j.gore.2015.07.004.
Samanta D, Lui F. Anti-NMDA Receptor Encephalitis. Treasure Island (FL): StatPearls Publishing, 2022.
Lin KL, Lin JJ. Neurocritical care for Anti-NMDA receptor encephalitis. Biomed J. 2020;43(3):251–258. doi: 10.1016/
Dalmau J, Armangué T, Planagumà J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18(11):1045–1057. doi: 10.1016/S1474– 4422(19)30244–3.
Lynch DR, Rattelle A, Dong YN, et al. Anti-NMDA Receptor Encephalitis: Clinical Features and Basic Mechanisms. Adv Pharmacol. 2018;82:235–260. doi: 10.1016/bs.apha.2017.08.005.
Kolls BJ, O’Keefe YA, Sahgal AK. Autoimmune Encephalitis: NMDA Receptor Encephalitis as an Example of Translational Neuroscience. Neurotherapeutics. 2020;17(2):404–413. doi: 10.1007/s13311–020– 00861–2.
Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63–74. doi: 10.1016/S1474–4422(10)70253–2.
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–65. doi: 10.1016/S1474–4422(12)70310–1.
Rypulak E, Borys M, Piwowarczyk P, et al. Successful treatment of anti- NMDA receptor encephalitis with a prompt ovarian tumour removal and prolonged course of plasmapheresis: A case report. Mol Clin Oncol. 2016;5(6):845–849. doi: 10.3892/mco.2016.1054.
Dalmau J, Geis C, Graus F. Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev. 2017 Apr;97(2):839–887. doi: 10.1152/ physrev.00010.2016.
Dalmau J, Rosenfeld MR. Paraneoplastic and autoimmune encephalitis. search=anti-n-methyl-d-aspartate%20receptor%20 antibodies%20encephalitis&source=search_result&selectedTitle=1~15 0&usage_type=default&display_rank=1#H3370789 (access: 2022.05.04).
Miao A, Du M, Wang L, et al. Analysis of Relation Between Electroclinical Features and Cerebrospinal Fluid Antibody Titers in Patients Withanti-NMDAR Encephalitis. Clin EEG Neurosci. 2019;50(1):56–62. doi: 10.1177/1550059418800867.
Gabilondo I, Saiz A, Galán L, et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology. 2011;6;77(10):996–9. doi: 10.1212/WNL.0b013e31822cfc6b.
Balu R, McCracken L, Lancaster E, Graus F, Dalmau J, Titulaer MJ. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology. 2019;15;92(3):e244-e252. doi: 10.1212/WNL.0000000000006783.
Vahabi Z, Etesam F, Zandifar A, et al. Anti N-Methyl-D-Aspartate (NMDA) receptor encephalitis: from psychosis to cognitive impairment. Clin Case Rep. 2021;9:2174–2178. doi: 10.1002/ccr3.3974.
Delangle R, Demeret S, Canlorbe G, et al. Anti-NMDA receptor encephalitis associated with ovarian tumor: the gynecologist point of view. Arch Gynecol Obstet. 2020;302(2):315–320. doi: 10.1007/s00404–020–05645–9.
Mann AP, Grebenciucova E, Lukas RV. Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management, and challenges. Ther Clin Risk Manag. 2014;1;10:517–25. doi: 10.2147/TCRM.S61967.